These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11299436)
21. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129 [TBL] [Abstract][Full Text] [Related]
22. Surgical Management of Tuberculosis-related Cerebral Disorders: A Retrospective Single-center Study. Seddighi AS; Seddighi A; Zali A Int J Mycobacteriol; 2024 Jul; 13(3):314-319. PubMed ID: 39277895 [TBL] [Abstract][Full Text] [Related]
23. Long-term follow up of childhood tuberculous meningitis. Schoeman J; Wait J; Burger M; van Zyl F; Fertig G; van Rensburg AJ; Springer P; Donald P Dev Med Child Neurol; 2002 Aug; 44(8):522-6. PubMed ID: 12206617 [TBL] [Abstract][Full Text] [Related]
24. Tuberculosis preventative treatment also prevented diarrhoea in HIV-infected patients in Zambia. Mwinga A; Hosp M; Zulu I; Farthing MJ; Mulambo S; Kelly P AIDS; 2002 Mar; 16(5):806-8. PubMed ID: 11964547 [No Abstract] [Full Text] [Related]
25. Management of central nervous system tuberculosis in children: light and shade. Buonsenso D; Serranti D; Valentini P Eur Rev Med Pharmacol Sci; 2010 Oct; 14(10):845-53. PubMed ID: 21222370 [TBL] [Abstract][Full Text] [Related]
26. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632 [TBL] [Abstract][Full Text] [Related]
27. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165 [TBL] [Abstract][Full Text] [Related]
28. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC; Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063 [TBL] [Abstract][Full Text] [Related]
29. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755 [TBL] [Abstract][Full Text] [Related]
30. [Epidural abscess due to a Mycobacterium tuberculosis strain with primary resistance to isoniazid and ethambutol]. Sener A; Akçalı A; Karatağ O; Koşar S; Değirmenci Y; Akman T Mikrobiyol Bul; 2012 Oct; 46(4):689-94. PubMed ID: 23188583 [TBL] [Abstract][Full Text] [Related]
31. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)]. Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070 [TBL] [Abstract][Full Text] [Related]
32. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. Sterling TR; Alwood K; Gachuhi R; Coggin W; Blazes D; Bishai WR; Chaisson RE AIDS; 1999 Oct; 13(14):1899-904. PubMed ID: 10513648 [TBL] [Abstract][Full Text] [Related]
33. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Stout JE Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147 [TBL] [Abstract][Full Text] [Related]
34. Pyrazinamide serum levels in childhood tuberculosis. Thee S; Detjen A; Wahn U; Magdorf K Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511 [TBL] [Abstract][Full Text] [Related]
35. Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant. Ishiwada N; Tokunaga O; Nagasawa K; Ichimoto K; Kinoshita K; Hishiki H; Kohno Y Tohoku J Exp Med; 2013 Mar; 229(3):221-5. PubMed ID: 23470647 [TBL] [Abstract][Full Text] [Related]
36. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488 [TBL] [Abstract][Full Text] [Related]
37. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909 [TBL] [Abstract][Full Text] [Related]
39. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398 [TBL] [Abstract][Full Text] [Related]
40. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]